NeuroTau, Inc. Report issue

For profit Phase 2
Founded: Warwick RI United States (2017)

Organization Overview

First Clinical Trial
2021
NCT04253132
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

NeuroTau, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

tolfenamic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Supranuclear Palsy, Progressive (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1